Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript Summary
Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript Summary
Gross margins improved to 60% in Q3 2024 from 59% in Q3 2023.The following is a summary of the Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript:
以下是aspira women's health公司（AWH）2024年第三季度业绩会议电话记录摘要：
Financial Performance:
财务表现：
OvaSuite revenue for Q3 2024 was $2.3 million, a 2% increase YoY, with test volumes increasing by 4%.
The average unit price of OvaSuite tests slightly decreased from $383 in Q3 2023 to $376 in Q3 2024.
Gross margins improved to 60% in Q3 2024 from 59% in Q3 2023.
Cash used in operating activities was $2.9 million, down 12% YoY.
OvaSuite在2024年第三季度的营业收入为230万美元，同比增长2%，检测量增加了4%。
OvaSuite测试的平均单价从2023年第三季度的383美元略微下降到2024年第三季度的376美元。
毛利率从2023年第三季度的59%提高到2024年第三季度的60%。
经营活动中使用的现金额为290万美元，同比下降12%。
Business Progress:
业务进展：
Launched OvaWatch in New York after receiving regulatory approval.
Announced a collaborative agreement with Dorsata to embed the OvaSuite test within EMR systems.
Received a $10 million ARPA-H federal award for the development of ENDOinform, a blood test for detecting endometriosis.
在获得监管批准后，于纽约推出了OvaWatch。
宣布与Dorsata达成合作协议，将OvaSuite测试嵌入EMR系统。
获得1000万美元的ARPA-H联邦奖励，用于开发ENDOinform，一种检测子宫内膜异位症的血液测试。
Opportunities:
机会：
Expanded commercial distribution of OvaWatch through BioReference labs.
Collaborated with leading medical institutions and received ARPA-H funding, emphasizing the commitment to advancing women's health diagnostics.
通过BioReference实验室扩展了OvaWatch的商业分销。
与领先的医疗机构合作并获得ARPA-H资金，强调致力于推进妇女健康诊断。
Risks:
风险：
Severe weather, including Hurricane Helene, adversely affected Q3 sales performance, indicating vulnerability to operational disruptions.
严重天气事件，包括飓风Helene，不利影响了第三季度的销售业绩，表明对运营中断的脆弱性。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
